国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (6): 703-709.doi: 10.7518/gjkq.2018.06.014

• 综述 • 上一篇    下一篇

骨硬化蛋白与牙周炎相关性的研究进展

许彩薇,薛毅(),吴仲寅   

  1. 白求恩国际和平医院口腔科 石家庄 050000
  • 收稿日期:2017-11-04 修回日期:2018-06-16 出版日期:2018-11-01 发布日期:2018-11-15
  • 通讯作者: 薛毅 E-mail:dentvip@qq.com
  • 作者简介:许彩薇,医师,硕士,Email: 834292608@qq.com
  • 基金资助:
    河北省2017年政府资助临床医学优秀人才培养和基础课题研究项目(2017-46)

Research progress on the relationship between periodontitis and sclerostin

Caiwei Xu,Yi Xue(),Zhongyin Wu   

  1. Dept. of Stomatology, Bethune International Peace Hospital, Shijiazhuang 050000, China
  • Received:2017-11-04 Revised:2018-06-16 Online:2018-11-01 Published:2018-11-15
  • Contact: Yi Xue E-mail:dentvip@qq.com
  • Supported by:
    This study was supported by The 2017 Heibei Provincial Government Foundation for Medical Talent Training and Fundamental Research(2017-46)

摘要:

牙槽骨破坏吸收是牙周炎的主要病理改变之一,骨硬化蛋白具有抑制成骨的特性,骨硬化蛋白抗体具有促进成骨的作用。近期研究表明,骨硬化蛋白在牙周炎的发生、发展中发挥重要作用。本文就骨硬化蛋白与牙周炎相关性的研究进展进行综述。

关键词: 牙周炎, 骨硬化蛋白, Wnt信号通路

Abstract:

Alveolar bone resorption is one of the main pathological changes brought about by periodontitis. Sclerostin is characterized by suppressing bone formation. Sclerostin antibody could promote bone formation. Sclerostin is involved in the occurrence and progression of periodontitis. This paper reviews the progress of research on the relationship between sclerostin and periodontitis.

Key words: periodontitis, sclerostin, Wnt signaling pathway

中图分类号: 

  • R781.4 +2
[1] Brunkow ME, Gardner JC, Van Ness J , et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein[J]. Am J Hum Genet, 2001,68(3):577-589.
doi: 10.1086/318811 pmid: 11179006
[2] Moester MJ, Papapoulos SE, Löwik CW , et al. Scle-rostin: current knowledge and future perspectives[J]. Calcif Tissue Int, 2010,87(2):99-107.
doi: 10.1007/s00223-010-9372-1
[3] van Lierop AH, Hamdy NA, van Egmond ME , et al. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers[J]. J Bone Miner Res, 2013,28(4):848-854.
doi: 10.1002/jbmr.1794 pmid: 23074140
[4] Gregson CL, Poole KE , McCloskey EV, et al. Eleva-ted circulating sclerostin concentrations in indivi-duals with high bone mass, with and without LRP5 mutations[J]. J Clin Endocrinol Metab, 2014,99(8):2897-2907.
doi: 10.1210/jc.2013-3958 pmid: 24606091
[5] Hay E, Bouaziz W, Funck-Brentano T , et al. Scle-rostin and bone aging: a mini-review[J]. Geronto-logy, 2016,62(6):618-623.
doi: 10.1159/000446278 pmid: 27177738
[6] Lewiecki EM . Sclerostin: a novel target for interven-tion in the treatment of osteoporosis[J]. Discov Med, 2011,12(65):263-273.
[7] Sharifi M, Ereifej L, Lewiecki EM . Sclerostin and skeletal health[J]. Rev Endocr Metab Disord, 2015,16(2):149-156.
doi: 10.1007/s11154-015-9311-6
[8] Winkler DG, Yu CP, Geoghegan JC , et al. Noggin and sclerostin bone morphogenetic protein anta-gonists form a mutually inhibitory complex[J]. J Biol Chem, 2004,279(35):36293-36298.
doi: 10.1074/jbc.M400521200 pmid: 15199066
[9] van Bezooijen RL, Roelen BA, Visser A , et al. Scle-rostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist[J]. J Exp Med, 2004,199(6):805-814.
doi: 10.1084/jem.20031454
[10] Yavropoulou MP, Yovos JG . The role of the Wnt signaling pathway in osteoblast commitment and differentiation[J]. Hormones (Athens), 2007,6(4):279-294.
doi: 10.14310/horm.2002.1111024 pmid: 18055419
[11] Graham JM, Ayati BP, Holstein SA , et al. The role of osteocytes in targeted bone remodeling: a mathe-matical model[J]. PLoS One, 2013,8(5):e63884.
doi: 10.1371/journal.pone.0063884 pmid: 23717504
[12] Tonna S, Sims NA . Talking among ourselves: para-crine control of bone formation within the osteoblast lineage[J]. Calcif Tissue Int, 2014,94(1):35-45.
doi: 10.1007/s00223-013-9738-2 pmid: 23695526
[13] Becker CB . Sclerostin inhibition for osteoporosis—a new approach[J]. N Engl J Med, 2014,370(5):476-477.
doi: 10.1056/NEJMe1315500 pmid: 24382003
[14] Sarahrudi K, Thomas A, Albrecht C , et al. Strongly enhanced levels of sclerostin during human fracture healing[J]. J Orthop Res, 2012,30(10):1549-1555.
doi: 10.1002/jor.v30.10
[15] Glass DA, Bialek P, Ahn JD , et al. Canonical Wnt signaling in differentiated osteoblasts controls osteo-clast differentiation[J]. Dev Cell, 2005,8(5):751-764.
doi: 10.1016/j.devcel.2005.02.017 pmid: 15866165
[16] Glass DA, Karsenty G . Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation[J]. Ann N Y Acad Sci, 2006,1068:117-130.
doi: 10.1196/annals.1346.015 pmid: 16831912
[17] Baron R, Hesse E . Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives[J]. J Clin Endocrinol Metab, 2012,97(2):311-325.
doi: 10.1210/jc.2011-2332 pmid: 22238383
[18] Canalis E, Giustina A, Bilezikian JP . Mechanisms of anabolic therapies for osteoporosis[J]. N Engl J Med, 2007,357(9):905-916.
doi: 10.1056/NEJMra067395 pmid: 17761594
[19] Evenepoel P , D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease[J]. Kidney Int, 2015,88(2):235-240.
doi: 10.1038/ki.2015.156 pmid: 26083653
[20] Burgers TA, Williams BO . Regulation of Wnt/β- catenin signaling within and from osteocytes[J]. Bone, 2013,54(2):244-249.
doi: 10.1016/j.bone.2013.02.022 pmid: 3652284
[21] Dallas SL, Prideaux M, Bonewald LF . The osteocyte: an endocrine cell . . and more[J]. Endocr Rev, 2013,34(5):658-690.
doi: 10.1210/er.2012-1026 pmid: 23612223
[22] Mattoo RL . The roles of fibroblast growth factor (FGF)-23, α-klotho and furin protease in calcium and phosphate homeostasis: a mini-review[J]. Indian J Clin Biochem, 2014,29(1):8-12.
doi: 10.1007/s12291-013-0324-1 pmid: 24478543
[23] Seifert ME, de las Fuentes L, Rothstein M , et al. Ef-fects of phosphate binder therapy on vascular stif-fness in early-stage chronic kidney disease[J]. Am J Nephrol, 2013,38(2):158-167.
doi: 10.1159/000353569 pmid: 3874122
[24] Lin CW, Jiang X, Dai ZQ , et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling[J]. J Bone Miner Res, 2009,24(10):1651-1661.
doi: 10.1359/jbmr.090411
[25] Kramer I, Loots GG, Studer A , et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice[J]. J Bone Miner Res, 2010,25(2):178-189.
doi: 10.1359/jbmr.090730 pmid: 3153379
[26] Ominsky MS, Vlasseros F, Jolette J , et al. Two doses of sclerostin antibody in cynomolgus monkeys in-creases bone formation, bone mineral density, and bone strength[J]. J Bone Miner Res, 2010,25(5):948-959.
doi: 10.1002/jbmr.14
[27] Padhi D, Jang G, Stouch B , et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody[J]. J Bone Miner Res, 2011,26(1):19-26.
doi: 10.1002/jbmr.173 pmid: 20593411
[28] Li XD, Ominsky MS, Warmington KS , et al. Sclero-stin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of pos-tmenopausal osteoporosis[J]. J Bone Miner Res, 2009,24(4):578-588.
doi: 10.1359/jbmr.081206 pmid: 19049336
[29] Tian XY, Setterberg RB, Li XD , et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow com-position in adult female rats[J]. Bone, 2010,47(3):529-533.
doi: 10.1016/j.bone.2010.05.032 pmid: 20561907
[30] Gori F, Hofbauer LC, Dunstan CR , et al. The expre-ssion of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated[J]. Endo-crinology, 2000,141(12):4768-4776.
[31] Wijenayaka AR, Kogawa M, Lim HP , et al. Scle-rostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway[J]. PLoS One, 2011,6(10):e25900.
doi: 10.1371/journal.pone.0025900
[32] Appelman-Dijkstra NM, Papapoulos SE . Sclerostin inhibition in the management of osteoporosis[J]. Calcif Tissue Int, 2016,98(4):370-380.
doi: 10.1007/s00223-016-0126-6 pmid: 23325222
[33] Kogawa M, Wijenayaka AR, Ormsby RT , et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2[J]. J Bone Miner Res, 2013,28(12):2436-2448.
doi: 10.1002/jbmr.2003 pmid: 23737439
[34] Napimoga MH , Nametala C, da Silva FL, et al. In-volvement of the Wnt-β-catenin signalling anta-gonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis[J]. J Clin Periodontol, 2014,41(6):550-557.
doi: 10.1111/jcpe.12245
[35] Lehnen SD, Götz W, Baxmann M , et al. Immunohis-tochemical evidence for sclerostin during cemento-genesis in mice[J]. Ann Anat, 2012,194(5):415-421.
doi: 10.1016/j.aanat.2012.02.014 pmid: 22560000
[36] Jäger A, Götz W, Lossdörfer S , et al. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro[J]. J Periodont Res, 2010,45(2):246-254.
doi: 10.1111/j.1600-0765.2009.01227.x pmid: 19778325
[37] 林婷婷, 陆尔奕 . SOST基因在人牙周膜细胞矿化诱导过程中的表达[J]. 上海口腔医学, 2012,21(2):139-144.
Lin TT, Lu EY . Effect of induced-mineralization on the expression of SOST in human periodontal liga-ment cells[J]. Shanghai J Stomatol, 2012,21(2):139-144.
[38] Kim JH, Lee DE, Cha JH , et al. Receptor activator of nuclear factor-κB ligand and sclerostin expression in osteocytes of alveolar bone in rats with ligature-induced periodontitis[J]. J Periodontol, 2014,85(11):e370-e378.
doi: 10.1902/jop.2014.140230 pmid: 25070541
[39] Kim JH, Lee DE, Woo GH , et al. Osteocytic sclero-stin expression in alveolar bone in rats with diabetes mellitus and ligature-induced periodontitis[J]. J Periodontol, 2015,86(8):1005-1011.
doi: 10.1902/jop.2015.150083 pmid: 25855571
[40] Veverka V, Henry AJ, Slocombe PM , et al. Charac-terization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation[J]. J Biol Chem, 2009,284(16):10890-10900.
doi: 10.1074/jbc.M807994200
[41] Poole KE, van Bezooijen RL, Loveridge N , et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation[J]. FASEB J, 2005,19(13):1842-1844.
doi: 10.1096/fj.05-4221fje pmid: 16123173
[42] Silvestrini G, Ballanti P, Leopizzi M , et al. Effects of intermittent parathyroid hormone (PTH) adminis-tration on SOST mRNA and protein in rat bone[J]. J Mol Histol, 2007,38(4):261-269.
doi: 10.1007/s10735-007-9096-3 pmid: 17549589
[43] Rooker SM, Liu B, Helms JA . Role of Wnt signaling in the biology of the periodontium[J]. Dev Dyn, 2010,239(1):140-147.
doi: 10.1002/dvdy.22003 pmid: 3280952
[44] Balli U, Aydogdu A, Dede FO , et al. Gingival cre-vicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in perio-dontitis[J]. J Periodontol, 2015,86(12):1396-1404.
doi: 10.1902/jop.2015.150270 pmid: 26367496
[45] Kim BJ, Bae SJ, Lee SY , et al. TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition[J]. Biochem Biophys Res Commun, 2012,424(1):170-175.
doi: 10.1016/j.bbrc.2012.06.100 pmid: 22735261
[46] Cenci S, Weitzmann MN, Roggia C , et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α[J]. J Clin Invest, 2000,106(10):1229-1237.
doi: 10.1172/JCI11066 pmid: 11086024
[47] Ryan MR, Shepherd R, Leavey JK , et al. An IL-7-dependent rebound in thymic T cell output contri-butes to the bone loss induced by estrogen deficiency[J]. Proc Natl Acad Sci USA, 2005,102(46):16735-16740.
doi: 10.1073/pnas.0505168102 pmid: 16267136
[48] Baek K, Hwang HR, Park HJ , et al. TNF-α upregu-lates sclerostin expression in obese mice fed a high-fat diet[J]. J Cell Physiol, 2014,229(5):640-650.
doi: 10.1002/jcp.24487
[49] Klein-Nulend J, Bacabac RG, Bakker AD . Mecha-nical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton[J]. Eur Cell Mater, 2012,24:278-291.
doi: 10.1101/cshperspect.a007435 pmid: 23007912
[50] Klein-Nulend J, Bakker AD, Bacabac RG , et al. Me-chanosensation and transduction in osteocytes[J]. Bone, 2013,54(2):182-190.
doi: 10.1138/20060233 pmid: 1847717
[51] Spatz JM, Fields EE, Yu EW , et al. Serum sclerostin increases in healthy adult men during bed rest[J]. J Clin Endocrinol Metab, 2012,97(9):E1736-E1740.
doi: 10.1210/jc.2012-1579 pmid: 22767636
[52] Frings-Meuthen P, Boehme G, Liphardt AM , et al. Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men[J]. J Musculoskelet Neuronal Interact, 2013,13(1):45-52.
doi: 10.1016/j.ijpsycho.2013.03.009 pmid: 23445914
[53] Ominsky MS, Li CY, Li XD , et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones[J]. J Bone Miner Res, 2011,26(5):1012-1021.
doi: 10.1002/jbmr.307 pmid: 21542004
[54] Li CY, Ominsky MS, Tan HL , et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene[J]. Bone, 2011,49(6):1178-1185.
doi: 10.1016/j.bone.2011.08.012 pmid: 21890008
[55] Taut AD, Jin QM, Chung JH , et al. Sclerostin anti-body stimulates bone regeneration after experimental periodontitis[J]. J Bone Miner Res, 2013,28(11):2347-2356.
doi: 10.1002/jbmr.1984 pmid: 23712325
[56] Kuchler U, Schwarze UY, Dobsak T , et al. Dental and periodontal phenotype in sclerostin knockout mice[J]. Int J Oral Sci, 2014,6(2):70-76.
doi: 10.1038/ijos.2014.12 pmid: 24699186
[57] Chen H, Xu XC, Liu M , et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of loca-lized periodontitis[J]. Bone, 2015,76:141-148.
doi: 10.1016/j.bone.2015.04.002 pmid: 25868799
[58] Ren YS, Han XL, Ho SP , et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model[J]. FASEB J, 2015,29(7):2702-2711.
doi: 10.1096/fj.14-265496
[59] Roguljic H, Matthews BG, Yang W , et al. In vivo identification of periodontal progenitor cells[J]. J Dent Res, 2013,92(8):709-715.
doi: 10.1177/0022034513493434 pmid: 23735585
[60] Rios HF, Ma D, Xie Y , et al. Periostin is essential for the integrity and function of the periodontal ligament during occlusal loading in mice[J]. J Perio-dontol, 2008,79(8):1480-1490.
doi: 10.1902/jop.2008.070624 pmid: 2581516
[1] 郭淑娟,刘倩,丁一. 牙周病和植体周病国际新分类简介[J]. 国际口腔医学杂志, 2019, 46(2): 125-134.
[2] 吕慧欣,杜留熠,王鹞,于维先,任静宜,顾芯铭,周延民. 炎症小体在牙周炎中的研究进展[J]. 国际口腔医学杂志, 2019, 46(2): 186-190.
[3] 聂然,郭天奇,李雪,裴婷婷,秦勤,周延民. 与牙周炎相关的组织蛋白酶研究进展[J]. 国际口腔医学杂志, 2019, 46(2): 197-202.
[4] 王鹞,吕慧欣,杜留熠,顾芯铭,任静宜,于维先,周延民. 软脑膜在外周炎症影响神经炎症过程中的作用[J]. 国际口腔医学杂志, 2019, 46(2): 223-227.
[5] 杨卓,张盛丹,刘程程,丁一. 侵袭性牙周炎唾液诊断标记物的研究进展[J]. 国际口腔医学杂志, 2019, 46(1): 55-61.
[6] 田江雪,莫龙义,贾小玥,刘程程,徐欣. 转化生长因子β在牙周炎发生发展中的作用及其机制[J]. 国际口腔医学杂志, 2018, 45(5): 553-559.
[7] 姜懿轩,莫龙义,贾小玥,徐欣,刘程程. 植物雌激素防治牙周炎的研究进展[J]. 国际口腔医学杂志, 2018, 45(5): 571-578.
[8] 黄海霞, 兰玉燕, 张昊, 潘兰兰, 郭玲, 刘敏. 慢性牙周炎患者种植修复后种植体牙周指数及龈沟液炎性因子水平的变化研究[J]. 国际口腔医学杂志, 2018, 45(4): 396-402.
[9] 杨鑫, 李思洁, 赵玮. Wnt信号通路在调控牙髓干细胞多向分化及炎症损伤修复中的作用[J]. 国际口腔医学杂志, 2018, 45(3): 286-290.
[10] 郑直, 颜世果. 疱疹病毒与牙周炎的关系[J]. 国际口腔医学杂志, 2018, 45(2): 224-227.
[11] 张鹏, 丁一, 王琪. 炎性衰老在糖尿病牙周炎中的作用机制及研究现状[J]. 国际口腔医学杂志, 2017, 44(6): 664-668.
[12] 吴琪, 刘程程, 郑黎薇, 李继遥, 周学东, 徐欣. 肠道微生物调控骨代谢的研究进展[J]. 国际口腔医学杂志, 2017, 44(6): 628-635.
[13] 唐秋玲, 李格格, 潘佳慧, 侯玉帛, 孟阳, 于维先. 细胞焦亡与牙龈卟啉单胞菌的关系及其在牙周病发生发展中的作用机制[J]. 国际口腔医学杂志, 2017, 44(6): 660-663.
[14] 李格格, 潘佳慧, 唐秋玲, 刘歆婵, 侯玉帛, 于维先. 牙龈素促进牙龈卟啉单胞菌免疫逃逸的机制[J]. 国际口腔医学杂志, 2017, 44(5): 519-522.
[15] 李琳, 王丹, 赵曼竹, 唐明. 慢性牙周炎与神经退行性疾病相关性的研究进展[J]. 国际口腔医学杂志, 2017, 44(5): 514-518.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张京剧. 青年期至中年期颅面复合体变化的头影测量研究[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 王昆润. 修补颌骨缺损的新型生物学相容材料[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 汤庆奋,王学侠. 17β-雌二醇对人类阴道和口腔颊粘膜的渗透性[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 高卫民,李幸红. 发达国家牙医学院口腔种植学教学现状[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 张新春. 桩冠修复与无髓牙的保护[J]. 国际口腔医学杂志, 1999, 26(06): .
[6] 彭国光. 颈淋巴清扫术中颈交感神经干的解剖变异[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 温秀杰. 氟化物对牙本质脱矿抑制作用的体外实验研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[8] 轩东英. 不同赋形剂对氢氧化钙抗菌效果的影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[9] 汪月月,郭莉莉. 口腔机能与老化—痴呆危险因素流行病学研究[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 孟姝,吴亚菲,杨禾. 伴放线放线杆菌产生的细胞致死膨胀毒素及其与牙周病的关系[J]. 国际口腔医学杂志, 2005, 32(06): 458 -460 .